London, May 9, 2026, 23:06 (BST)
- Compass Group PLC is set to release its 2026 half-year numbers at 7 a.m. BST on Monday. Management will hold a presentation at 9 a.m., followed by a Q&A session after the webcast.
- CPG finished Friday’s session with shares offered at $29.51 on the sell side and $29.52 to buy, a 0.73% gain, according to Hargreaves Lansdown data with the market now shut.
- The company most recently stuck with its 2026 outlook, projecting roughly 10% growth in underlying operating profit at constant currency—driven by about 7% organic revenue growth and contributions from M&A.
With half-year numbers due Monday, Compass Group PLC faces investor scrutiny over its ability to hold on to its 2026 profit target. The catering firm’s performance in workplace dining, growth tied to technology clients, and integration of its bigger European division are all in the spotlight.
The timing is key here. The update lands before London traders return for a full day, and since April 1, Compass shares have started quoting in U.S. dollars instead of sterling pence on the London Stock Exchange. Compass has said the currency switch is aimed at cutting FX swings in the share price, with no impact on its LSE listing or FTSE index status.
Compass heads into results with a little cover. Back in February, the company reported first-quarter organic revenue up 7.3%, matching that pace in North America and hitting 7.1% for International. Client retention stayed above 96%. Annualised new business wins came in at $4 billion, and the North American Business & Industry arm delivered double-digit growth.
Analyst expectations are largely in line with what management has signaled. As of March 2, Compass’s posted consensus calls for 7.2% organic revenue growth in fiscal 2026, with revenue set at $50.5 billion and underlying operating profit coming in at $3.72 billion. The underlying profit figure reflects Compass’s adjusted metric; results on a constant currency basis exclude exchange-rate swings.
Back in February, Chief Executive Dominic Blakemore told analysts Compass had kicked off the year “strong.” Finance chief Petros Parras pointed to volumes boosting results by around half a percentage point in Q1. Blakemore added that, assuming retention holds up, net new business might edge higher in the second half.
The sentiment piece is trickier. Back in February, Reuters noted that Compass shares slipped despite a revenue beat, with investors eyeing how artificial intelligence might impact office-heavy clients. Tech, professional, and financial services firms make up roughly 20% of Compass’s revenue. Blakemore, addressing analysts at the time, said he believed there was “more opportunity than risk” tied to AI. Reuters
The problem lingered. On the February call, executives put 80% of the portfolio in sports, defence, mining, manufacturing, education, and healthcare—industries they argued were mostly shielded from AI disruption. But Citi’s Leo Carrington and UBS’s Ivar Billfalk-Kelly weren’t convinced; they pushed for details on office properties and whether falling attendance might squeeze contract economics.
M&A remains in focus. In December, Compass wrapped up its $1.7 billion acquisition of Dutch food-services group Vermaat—part of $1.9 billion in M&A spend for the first quarter. Management pitched the move as a strategic push to boost capabilities in Europe and repeat its North American deals strategy. Even so, Parras told analysts details on integration would have to wait—still too early.
The sector picture is patchy, and hardly ideal. Back in April, French rival Sodexo slashed its 2026 sales and margin forecasts, blaming execution hiccups along with a review of its contracts and assets. That move sent Sodexo shares tumbling 13% on the day, Reuters reported, and the company had already lagged behind Compass and Aramark across the previous two years. Morningstar’s Ben Slupecki pointed to mounting Aramark competition as a possible factor behind some of Sodexo’s U.S. stumbles, according to Reuters.
Compass faces a potential hit if Monday’s update reveals North American Business & Industry growth losing steam, lighter client volumes, tighter margins, or a more reserved outlook on Vermaat. Investors will be tuned in for any change of tone on GLP-1 drugs — used for diabetes and weight loss — after Blakemore’s February comments that Compass hadn’t noticed any effect yet, though menu tweaks and portion adjustments were on the table if trends start to shift.
The next trading update lands July 21, and full-year numbers are set for Nov. 24. Monday brings half-year results—those will put February’s guidance to the test, and could shift the conversation to valuation, AI-driven office demand, and the pace at which acquisitions start to deliver returns.
